No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

Higher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide ...

The cost of Ocrevus can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Ocrevus. As with all ...

In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus (ocrelizumab). The company announced that a phase III study, MUSETTE ...

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and ...

MUSETTE trial was designed to determine whether a higher dose of the currently approved Ocrevus IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis ...